ONCT News and Press, Oncternal Therapeutics Inc. From 05/09/20

Oncternal Therapeutics, Inc. (ONCT) Q1 2020 Earnings Conference Call May 7, 2020, 05:00 PM ET Company Participants Richard Vincent - CFO Jim Breitmeyer - President and CEO Frank Hsu - Chief Medical Officer Conference Call Participants Hartaj Singh - Oppenheimer Carl Byrne...

Oncternal Therapeutics (NASDAQ: ONCT ): Q1 GAAP EPS of -$0.31. More news on: Oncternal Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

- Deep clinical responses reported for two of seven patients with relapsed/refractory Ewing sarcoma treated with the recommended Phase 2 dose of TK216 in ongoing Phase 1 clinical trial - 50% complete response rate reported in patients with relapsed/refractory MCL in ongoing Phase 1/2 ...

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report first quarter 2020 financial results after the U.S. financial markets close on Thursday, May 7, 2020. Oncternal&#...

Oncternal Therapeutics, Inc. (ONCT) Q4 2019 Results Conference Call March 16, 2020 04:30 PM ET Company Participants Richard Vincent - CFO Dr. Jim Breitmeyer - President and CEO Dr. Frank Hsu - Chief Medical Officer Conference Call Participants Hartaj Singh - Oppenheimer M...

Oncternal Therapeutics (NASDAQ: ONCT ): Q4 GAAP EPS of -$0.27. More news on: Oncternal Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

- Steady progress of clinical programs in four indications: MCL, Ewing sarcoma, breast cancer, and CLL - Cirmtuzumab in combination with ibrutinib demonstrated a 50% CR rate and 83% best ORR in patients with relapsed/refractory MCL in an interim analysis from an ongoing Phase 1/2 cl...

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report its fourth quarter and full year 2019 financial results on March 16, 2020. Oncternal’s management will hos...

Preliminary results from a Phase 1/2 clinical trial evaluating Oncternal Therapeutics' ( ONCT +4.3% ) lead candidate cirmtuzumab, combined with AbbVie and J&J's Imbruvica (ibrutinib), in blood cancer patients showed encouraging action in a subset of participants with relapsed/refr...

50% (six of twelve) evaluable patients with relapsed/refractory MCL achieved complete responses (CR) in the dose-finding cohort of the ongoing Phase 1/2 clinical trial 83% best objective response rate (ORR) and 100% clinical benefit rate Oncternal Therapeutics, Inc. (Nasdaq: ...